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1. Introduction
  Obstructive sleep apnea-hypopnea syndrome (OSAHS) is 
a common, serious disease characterized by complete or 
partial upper airway closure during sleep that results in 
periodic nocturnal oxyhemoglobin desaturation and sleep 
fragmentation. OSAHS commonly affects the cardiovascular, 
nervous, and endocrine systems, among others. Cognitive 
impairment is the major complication of the nervous 
system in OSAHS. Studies showed that this condition can 
cause adult dementia[1]. Sleep fragmentation, repetitive 
nocturnal hypoxemia, and daytime sleepiness are suggested 
to contribute to the cognitive deficit in OSAHS[2]. However, 
although some researchers believe that this hypothesis can 
be proven by further experiments[3], how these factors affect 
cognition is unclear. 
  Brain-derived neurotrophic factor (BDNF) is a protein 
produced by brain tissues. BDNF is the most abundant 
and widely distributed member of the neurotrophic factor 
family[4]. A number of studies proved the importance of 
BDNF in the differentiation, development, growth, and 
regeneration of the nervous system[5,6]. BDNF is also 
suggested to be closely associated with cognition. Li et 
al[7] reported that age-related cognitive decline (ARCD) 
patients have significantly decreased serum blood BDNF 
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levels compared with healthy people. Caccamo et al[8,9] 
found that BDNF is correlated with cognitive impairment in 
Alzheimer’s disease (AD) and type 2 diabetes mellitus (DM) 
patients. Several studies have demonstrated the relationship 
of BDNF with cognitive impairment in OSAHS, but the 
results are inconsistent. Wang et al reported that OSAHS 
children with cognitive impairment whose blood serum 
BDNF levels were significantly decreased compared with 
the control group[10]. Another study on adult OSAHS patients 
with cognitive deficit carried out by Hu et al had similar 
results[11]. Staats et al suggested that there is no significant 
difference in serum and plasma BDNF level between OSAHS 
patients and control group[12]. In the present study, we 
hypothesized that the serum BDNF level of OSAHS patients 
changed compared with healthy people and it related with 
their cognitive function. Thus, we determined the blood 
serum BDNF levels of middle-aged OSAHS men as well as 
explored the relationship of their cognitive deficit with sleep 
fragmentation and hypoxia/hypopnea to offer new clues to 
the mechanism of cognitive impairment in OSAHS patients. 
2. Materials and methods
2.1. Subjects
  From February 2011 to October 2011, 28 Han Chinese 
OSAHS male patients and 14 healthy volunteers aged 40-
49 years were recruited to participate in this controlled, 
randomized, open-labeled study at the First Affiliated 
Hospital of Hunan Normal University. The inclusion criteria 
for OSAHS patients were as follows: newly diagnosed OSAHS 
by polysomnography according to standard criteria[13], 
apnea-hypopnea index (AHI) 曒5 without any previous 
therapy, and educational attainment higher than middle 
school. The exclusion criteria were as follows: history of 
chronic obstructive pulmonary disease, cardiovascular 
disease, hematological disorders, nephritic disease, nervous 
system diseases and injury, as well as diseases of the 
endocrine system; abnormal hepatic function; history of 
taking hormones, sedatives, and antipsychotics, as well 
as excessive drinking (>80 g/d); and concurrent oncologic 
diseases. 
  The control group comprised individuals who were proved 
to be healthy and OSAHS free by polysomnography (PSG) and 
medical examination.
  This study was approved by the Ethics Committee of Hunan 
Normal University. Written informed consent was obtained 
from all participants before the start of the study.
 
2.2. Treatments
2.2.1. PSG
  OSAHS was diagnosed using PSG. OSAHS was defined based 
on the American Association of Sleep Disorder standards. 
Within 24 h before PSG, the subjects were not allowed to take 
sedatives as well as drink alcohol, tea, and coffee. They were 
put to sleep for 7.5 h from 10:30 pm to 6:00 am. The main 
indicators of PSG included AHI, lowest SaO2 (LSO), duration 
of sleep stage 栺(S1) (%), sleep stage 栻(S2) (%), sleep stage栿 
(S3) (%), sleep stage 桇 (S4) (%), and rapid eye movement sleep 
(REM) (%). The PSG results were examined and approved by 
the same doctor in the sleep center. 
2.2.2. Cognitive function
 Cognitive function was evaluated using the Montreal 
cognitive assessment (MoCA) that evaluates executive 
function, naming, attention, calculation, language, 
abstraction, memory, and orientation. The total MoCA 
score is 30. A total MoCA score <26 indicates cognitive 
impairment, whereas a score 曒26 indicates normal cognitive 
function. If the schooling length of the subject was less than 
12 years, 1 point was added to the total score to adjust for 
educational bias[14]. The PSG lasted for 10 min.
2.2.3. Serum sample collection and BDNF measurement
  From 6:30 am to 7:00 am, 3 mL of blood was collected 
from the cubital veins before breakfast on the morning after 
PSG monitoring. Blood was allowed to coagulate for 10-20 
min at room temperature and centrifuged for about 20 min 
(3 000 rpm). Serum was collected and stored in a refrigerator 
at -80 曟. BDNF was measured using an enzyme-linked 
immunosorbent assay  kit purchased from R&D.
2.3. Statistical analysis
  Statistical analyses were performed using SPSS 17.0 
for Windows. For continuous variables, all values were 
expressed as mean暲standard deviation. The means 
between two groups were compared using the t test. Pearson 
correlation coefficient analysis was performed for variable 
correlation. The statistical significance level was set at two-
sided 毩 = 0.05.
3. Results
  Twenty-eight male OSAHS patients aged 40-49 years 
[average = (44.93暲2.98) years] participated in this study. All 
subjects had educational attainments higher than middle 
school, with an average length of education of (14.43暲
1.99) years. The maximal, minimal, and average body mass 
indices (BMI) were 34.80, 21.71, and (28.69暲3.70) kg/m
2. 
Fourteen healthy male volunteers aged 40-49 years [average 
= (44.79暲2.58) years] were included in the study. All 
volunteers had educational attainments higher than middle 
school, with an average length of education of (14.43暲1.99) 
years. The maximal, minimal, and average BMIs were 33.10, 
23.38, and (27.42暲2.80) kg/m
2, respectively. No significant 
difference was found in the age, schooling length, and BMI 
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between the OSAHS and control groups (Table 1). These 
results indicated that the study groups had comparable 
baseline data. 
  The OSAHS group had significantly higher AHI than the 
control group (Table 2). LSO was significantly decreased, 
and shallow sleep (S1+S2) was significantly extended in the 
OSAHS group. Slow wave sleep (S3+S4) and REM were also 
significantly reduced.
Table 1
Baseline socio-demographic characteristics of the OSAHS and 
control groups.
Characters OSAHS
group(n=28)
Control
group(n=14)
t P
Age (years) 44.93暲2.98 44.79暲2.58 0.153 0.879
Length of schooling
(years)
14.43暲1.99 14.21暲1.76 0.341 0.735
BMI (kg/m2) 28.69暲3.70 27.42暲2.80 1.124 0.268
Table 2
Conditions of sleep and respiration of the OSAHS and control groups 
(mean暲SD).
Indexes OSAHS
group(n=28)
Control
group(n=14)
t P
AHI (times/
h)
49.63暲28.56   2.27暲1.21   8.757* 0.000
LSO (%) 67.92暲12.66 89.64暲5.95 -7.556 0.000
S1+S2 (%) 76.75暲6.33 25.96暲6.82   23.899 0.000
S3+S4 (%) 10.24暲2.84 37.36暲12.76 -7.859* 0.000
REM (%)   5.78暲2.71 22.02暲5.51 -10.411 0.000
Note: *t’ value.
  
  Table 3 shows that the OSAHS group had significantly 
decreased total MoCA scores as well as scores of executive 
function, calculation, abstraction, and memory compared 
with the control group (P < 0.05).
  The mean serum BDNF level of the OSAHS group was (5.01
暲0.61) ng/mL, whereas that of the control group was (7.27
暲0.68) ng/mL. The serum BDNF level of the OSAHS patients 
were significantly decreased compared with the control 
group (t = -10.912, P = 0.000).
Table 3
Cognitive function of the OSAHS and control groups (mean暲SD).
C o g n i t i v e 
function
OSAHS group 
(n = 28 )
 Control group 
(n = 14 )
t P
Tota l  MoCA 
score
24.04暲1.75 28.57暲1.09  -8.835   0.000**
E x e c u t i v e 
function
  3.39暲0.92   4.86暲0.36  -7.375   0.000**
Naming   2.79暲0.42   2.86暲0.53  -0.475   0.637
Attention   2.39暲0.49   2.57暲0.51  -1.085   0.284
Calculation   2.54暲0.51   2.86暲0.36  -2.355   0.024*
Language   2.54暲0.74   2.71暲0.47  -0.817   0.419
Abstraction   1.61暲0.50   2.14暲0.36  -3.965   0.000**
Memory   3.14暲0.76   4.50暲0.52  -6.027   0.000**
Orientation   5.57暲0.50   5.79暲0.43  -1.444   0.159
Note: *P < 0.05, **P < 0.01.
 Table 4 shows that the total MoCA score of the subjects 
was significantly positively associated with the blood serum 
BDNF level (r = 0.544, P = 0.000) (Table 4). The scores of 
executive function (r = 0.550, P = 0.000), abstraction (r = 
0.408, P = 0.007), and memory (r = 0.509, P = 0.001) were 
also significantly positively associated with the blood 
serum BDNF level. The serum BDNF level had no significant 
difference from the age, BMI, and schooling length.
  Table 5 shows that the serum BDNF level had no correlation 
with the age, BMI, and schooling length. The serum BDNF 
level was significantly negatively correlated with the AHI 
and S1+S2, but significantly positively correlated with the 
LSO, S3+S4, and REM.
Table 4
Correlation of the MoCA score with the age, BMI, schooling length, 
and blood serum BDNF level.
Indexes Age BMI Schooling length BDNF (ng/mL )
Total MoCA 
score
-0.307 -0.274   0.113    0.544**
E x e c u t i v e 
function
-0.295 -0.243   0.197    0.550**
Naming -0.219 -0.138   0.140   0.176
Attention -0.040 -0.302   0.184   0.047
Calculation -0.289 -0.010   0.152   0.162
Language -0.090 -0.176 -0.025   0.039
Abstraction   0.238 -0.087 -0.307   0.408**
Memory -0.088 -0.063 -0.064   0.509**
Orientation           0.095 -0.211 -0.163   0.047
Note: All values in the table are expressed as r. Pearson correlation 
coefficient analysis was performed to analyze the relationship of the 
MoCA score with the age, BMI, schooling length, and blood serum 
BDNF level. *P < 0.05, **P < 0.01.
Table 5
Correlation analysis of the serum BDNF level with the age, BMI, 
schooling length, and sleep structure.
Indexes r P
Age   0.072 0.653
BMI -0.020 0.900
Length of schooling -0.010 0.952
AHI (times/h ) -0.607** 0.000
LSO (% )   0.566** 0.000
S1+S2 (% ) -0.768** 0.000
S3+S4 (% )   0.778** 0.000
REM (% )   0.575** 0.000
4. Discussion
  The mechanism of cognitive impairment in OSAHS patients 
is unclear. Animal experiments showed that BDNF mRNA 
expression in the hippocampus especially in the CA2 
and CA3 areas are closely associated with learning and 
memory[15]. BDNF and its receptor are involved in long-term 
potentiation by regulating the cholinergic system of the basal 
forebrain, synaptic transmission, and synaptic plasticity, as 
well as by affecting learning and memory[16]. Researchers 
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argued that reduced BDNF production in the cortex and 
hippocampus can lead learning and memory degradation[17].
  Compared with the control group, the AHI of the OSAHS 
group was significantly higher, the LSO was significantly 
decreased, shallow sleep (S1+S2) was significantly extended, 
and both slow wave sleep (S3+S4) and REM were significantly 
reduced. These results suggested that the OSAHS patients 
had nocturnal hypoxemia and sleep disturbance. The OSAHS 
patients had poorer cognitive function than the control 
group. Their executive function, calculation, memory, and 
abstraction were also significantly decreased compared with 
the control group. These results well agreed with previous 
results[18,19].
  The serum BDNF level of the subjects was detected using 
ELISA. Considering cognitive function and serum BDNF level 
were influenced by sex, age, education degree, other diseases 
and so on, abovementioned factors were controlled for 
subjects in this study. The OSAHS patients had significantly 
decreased serum BDNF levels compared with the controls. 
This finding suggested that the synthesis and release of 
BDNF in the OSAHS patients were inhibited. This result was 
similar to that obtained by Wang et al[10]. Further analysis on 
the relationship between cognitive function and the serum 
BDNF level was performed. The serum BDNF level was 
significantly positively correlated with the total MoCA score 
as well as the scores of executive function, memory, and 
abstraction. Thus, a higher serum BDNF level corresponded 
to better cognitive function, executive function, memory, 
and abstraction. These results are consistent with those 
obtained by previous researchers[20]. Although references on 
the correlation between BDNF and OSAHS are limited, the 
close correlation between BDNF and cognition was proved 
in several studies on cognitive deficit in AD, ARCD, and 
type 2 DM. It is reported that the serum and cerebrospinal 
fluid BDNF levels of AD patients are significantly decreased 
compared with controls, and decrease with age in healthy 
individuals[21,22]. McLay et al[23] used a Morris water maze to 
test the memory and learning ability of rats. They found that 
aged rats have poorer memories and learning abilities than 
younger rats, and the cognitive function of rats is negatively 
correlated with the neuron density and BDNF gene expressed 
in the hippocampus. Other studies suggested that the serum 
and plasma BDNF levels of type 2 DM patients are lower 
than those of healthy people, and this variety is correlated 
with their cognitive degradation. Researchers suggested 
that adequate blood BDNF concentrations can stop cognitive 
impairment[24-27]. Based on previous studies and the present 
one, we supposed that the decrease in serum BDNF is one of 
the biochemical mechanisms of cognitive deficit in OSAHS 
patients.
  To determine the reason for the declined serum BDNF 
level of OSAHS patients, we analyzed the relationship 
between the serum BDNF level and sleep structure of the 
subjects. We found that the serum BDNF level was closely 
negatively correlated with the time percentages of stages 1 
and 2 sleeps, but closely positively correlated with the time 
percentages of stage 3 and 4 sleep, as well as with REM. A 
longer time of shallow sleep or shorter time of slow wave 
sleep corresponded to lower serum BDNF levels. Thus, 
extending shallow sleep or shortening deep sleep and REM 
sleep may lead to declined serum BDNF levels in OSAHS 
patients. Hiroyoshi et al[28-30] reported that the cerebellar 
and brainstem BDNF levels of rats decline after 6 h of REM 
sleep deprivation. They suggested that a shortened REM time 
explains the reduction in BDNF secretion and release. Ugo et al[30] 
proved that the synthesis and release of BDNF occur in the 
brain during the period of slow wave sleep. After exogenous 
BDNF is injected into the cerebral hemispheres of rats, the 
animals can more deeply sleep than untreated rats. They 
believed that BDNF is important in slow wave sleep and 
both conditions regulate each other. Based on our study, 
we suggest that the decreased serum BDNF levels of OSAHS 
patients is due to a sleep structural disorder, particularly, 
significantly shortened slow wave and REM sleep, which 
lead to cognitive dysfunction.
  Nocturnal hypoxemia and the serum BDNF level were 
correlated. We found that the serum BDNF level was 
significantly negatively correlated with the AHI, but 
significantly positively correlated with the LSO. Thus, a 
higher severity of apnea/hyponea in OSAHS patients resulted 
in lower serum BDNF levels. This finding suggested that the 
serum BDNF level of OSAHS patients was closely related to 
the severity of nocturnal hypoxemia. Samantha et al[31] found 
that intermittent hypercapnic hypoxia upregulated apoptotic 
promoters and downregulated apoptotic inhibitors in the 
developing hippocampus of a piglet. Based on our findings, 
we speculate that nocturnal hypoxemia can promote 
neuronal apoptosis in the cerebral regions that are closely 
related with cognition, resulting in lower-than-normal 
levels of BDNF and its receptor. 
  In conclusion, the decrease in the serum BDNF levels of 
OSAHS patients is probably one of the mechanisms that lead 
to cognitive impairment as a result of nocturnal hypoxemia 
as well as deprived slow wave sleep and REM.
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